,166 Rates of incident hypertension, however, did not differ by high-sensitivity C-reactive protein tertiles; nor did canakinumab demonstrate a reduction in incident hypertension [HR: 0.96 (0.85–1.08), P > 0.2]. This evidence concerns the gene CRP and Hypertension.